title: [Effect of statin treatment begun early after acute myocardial infarction on endothelial function in patients with normal levels of cholesterol. VAATOPE Study (VAlue of ATOrvastatin in Postinfarction Endothelium)].
abstract: OBJECTIVE
  Recent studies have suggested that statins reduce the rate of subsequent coronary events when these drugs are indicated early alter an acute coronary event. One potential mechanism by which these drugs might reduce the likelihood of such events is by enhancing endothelial function. The aim of this study was to determine whether early cholesterol reduction with atorvastatin improved endothelial function after acute myocardial infarction in patients with normal cholesterol levels.
  
  
  METHODS
  Patients with a first acute myocardial infarction and normal levels of cholesterol were assigned to treatment with 10 mg atorvastatin (n = 15) or placebo (n = 15) for 8 weeks. Patients who had previously received treatment with statins were excluded. Brachial ultrasound was used to measure endothelium-dependent flow-mediated dilation and response to endothelium-independent nitroglycerin. Total and LDL cholesterol levels and the distribution of risk factors were similar on admission and before randomization in both groups. All patients were assessed between 5 and 7 days postinfarction and after 8 weeks.
  
  
  RESULTS
  Total and LDL cholesterol levels were significantly decreased after atorvastatin treatment. Total cholesterol decreased by 11% (p < 0.01) and LDL cholesterol by 18% (p < 0.01). Without atorvastatin flow-mediated dilation was unchanged (mean [SEM] 9.3 [1.7%] to 10.6 [1.7%]) but it increased with atorvastatin (8.9 [1.4%] to 16.5 [1.7%], p < 0.05). The response to nitroglycerin was similar in both groups during the period of study.
  
  
  CONCLUSIONS
  The early administration of atorvastatin appears to enhance endothelial function in patients with acute myocardial infarction and normal levels of cholesterol.
authors.affiliation: Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain.
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Gómez-Doblas
authors.forename: Manuel F
authors.initials: MF
authors.lastname: Jiménez-Navarro
authors.forename: José M
authors.initials: JM
authors.lastname: García-Pinilla
authors.forename: Isabel
authors.initials: I
authors.lastname: Rodríguez-Bailón
authors.forename: Juan
authors.initials: J
authors.lastname: Robledo
authors.forename: Fernando
authors.initials: F
authors.lastname: Cabrera
authors.forename: Salvador
authors.initials: S
authors.lastname: Espinosa
authors.forename: Eduardo
authors.initials: E
authors.lastname: de Teresa
mesh_terms: D000368:Aged; D000069059:Atorvastatin; D001916:Brachial Artery / Q000000981:diagnostic imaging; D004730:Endothelium, Vascular / Q000187:drug effects*; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000517:prevention & control*; D011758:Pyrroles / Q000627:therapeutic use*; D014463:Ultrasonography
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008074:Lipoproteins; D011758:Pyrroles; D000069059:Atorvastatin